Appili Price To Sales Ratio from 2010 to 2026
| APLI Stock | CAD 0.02 0.01 20.00% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 48.59 | Current Value 40.48 | Quarterly Volatility 49.26411672 |
Check Appili Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Appili Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.6 M, Depreciation And Amortization of 11.3 K or Interest Expense of 4.2 M, as well as many indicators such as Price To Sales Ratio of 40.48, Dividend Yield of 0.0 or Days Sales Outstanding of 5.7 K. Appili financial statements analysis is a perfect complement when working with Appili Therapeutics Valuation or Volatility modules.
Appili | Price To Sales Ratio |
Evaluating Appili Therapeutics's Price To Sales Ratio across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Appili Therapeutics's fundamental strength.
Latest Appili Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Appili Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Appili Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Appili Therapeutics sales, a figure that is much harder to manipulate than other Appili Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Appili Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Appili Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 11.76 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Appili Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 78.46 | |
| Geometric Mean | 50.63 | |
| Coefficient Of Variation | 62.79 | |
| Mean Deviation | 45.61 | |
| Median | 117.23 | |
| Standard Deviation | 49.26 | |
| Sample Variance | 2,427 | |
| Range | 112 | |
| R-Value | (0.77) | |
| Mean Square Error | 1,042 | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (7.54) | |
| Total Sum of Squares | 38,831 |
Appili Price To Sales Ratio History
About Appili Therapeutics Financial Statements
Appili Therapeutics investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Appili Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 48.59 | 40.48 |
Pair Trading with Appili Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Appili Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Appili Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Appili Stock
| 0.42 | ETG | Entree Resources | PairCorr |
| 0.39 | NICU | Magna Mining | PairCorr |
| 0.36 | ILI | Imagine Lithium | PairCorr |
| 0.35 | AIM | Aimia Inc | PairCorr |
| 0.35 | CU-PH | Canadian Utilities | PairCorr |
The ability to find closely correlated positions to Appili Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Appili Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Appili Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Appili Therapeutics to buy it.
The correlation of Appili Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Appili Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Appili Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Appili Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.